Trial Profile

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 May 2026 Primary endpoint (Change from Baseline in skeletal abnormalities as measured by the Radiographic Global Impression of Change (RGI-C) global score through Week) has not been met, according to a BioMarin Pharmaceutical Media Release.
18 May 2026 According to the BioMarin Pharmaceutical Media Release, detailed results from the ENERGY 3 study will be presented at an upcoming medical meeting.
18 May 2026 Primary endpoint (Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) concentration through Week 52) has been met, according to a BioMarin Pharmaceutical Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com